phenobarbital has been researched along with Depression in 36 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Scopus, ISI, Embase, PubMed, Cochrane Library, Google Scholar, and two trial registries were searched for randomized controlled trials on the effectiveness of topiramate, phenobarbital, and other ten barbiturates in depression." | 9.22 | Topiramate and other kainate receptor antagonists for depression: A systematic review of randomized controlled trials. ( Shamabadi, A, 2022) |
| " Scopus, ISI, Embase, PubMed, Cochrane Library, Google Scholar, and two trial registries were searched for randomized controlled trials on the effectiveness of topiramate, phenobarbital, and other ten barbiturates in depression." | 5.22 | Topiramate and other kainate receptor antagonists for depression: A systematic review of randomized controlled trials. ( Shamabadi, A, 2022) |
| "This review does not provide sufficient evidence to support levetiracetam, phenobarbital or lamotrigine for the treatment of epilepsy in people with Alzheimer's disease." | 5.12 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN, 2021) |
| "Phenazepam given to rats in a daily dose of 2 mg/kg intraperitoneally for a long (30 days) time ceased to produce the sedative effect, and discontinuation of the medication led to development of the so-called "recoil syndrome" characterized by general depression and disturbances of the conditioned-reflex activity." | 3.66 | [Experimental study of the "'rebound syndrome" following discontinuation of prolonged phenazepam administration and possibilities for preventing it]. ( Garibova, TL; Voronina, TA, 1981) |
| "Any type of seizure can be observed in Alzheimer's disease (AD)." | 2.58 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2018) |
| "Any type of seizure can be observed in Alzheimer's disease (AD)." | 2.53 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2016) |
| " This dose-response relationship suggests that (1) REM pressure was an indicator of a process that mediated the antidepressant effects of REM sleep deprivation, and (2) since improvement varied with stimulation of REM sleep, an unknown stimulus of REM sleep is a naturally occurring, endogenous antidepressant." | 1.26 | Endogenous depression improvement and REM pressure. ( Barker, K; McAbee, R; Thurmond, A; Vogel, GW, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 2 (5.56) | 24.3611 |
| 2020's | 3 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Shamabadi, A | 1 |
| Minissale, MG | 1 |
| Giannitrapani, L | 1 |
| Capitano, A | 1 |
| Morreale, I | 1 |
| Licata, A | 1 |
| Liu, J | 3 |
| Wang, LN | 3 |
| Wu, LY | 2 |
| Wang, YP | 2 |
| THOMPSON, LJ | 1 |
| PROCTOR, RC | 1 |
| MARSH, DO | 1 |
| SCHNIEDEN, H | 1 |
| MARSHALL, J | 1 |
| BLACHLY, PH | 1 |
| CHARRIOT, G | 1 |
| LAMBERT, PA | 1 |
| NORRIS, AS | 1 |
| RYPSON, L | 1 |
| ZIELINSKI, J | 1 |
| PRESTON, DN | 1 |
| ATACK, EA | 1 |
| KAST, EC | 1 |
| WRIGHT, JA | 1 |
| Kemp, S | 1 |
| Feely, M | 1 |
| Hay, A | 1 |
| Wild, H | 1 |
| Cooper, C | 1 |
| Mailman, RB | 1 |
| Frye, GD | 1 |
| Mueller, RA | 1 |
| Breese, GR | 1 |
| Guliamov, MG | 1 |
| Voronina, TA | 1 |
| Garibova, TL | 1 |
| Vogel, GW | 1 |
| McAbee, R | 1 |
| Barker, K | 1 |
| Thurmond, A | 1 |
| Rosalki, SB | 1 |
| Tarlow, D | 1 |
| Rau, D | 1 |
| Marsden, CD | 1 |
| Reynolds, EH | 1 |
| Parsons, V | 1 |
| Harris, R | 1 |
| Duchen, L | 1 |
| Kristianson, P | 1 |
| Wheatley, D | 2 |
| Snaith, RP | 1 |
| McCoubrie, M | 1 |
| Uhlenhuth, EH | 1 |
| Stephens, JH | 1 |
| Dim, BH | 1 |
| Covi, L | 1 |
| Hollister, LE | 1 |
| Rickels, K | 1 |
| Chung, HR | 1 |
| Feldman, HS | 1 |
| Gordon, PE | 1 |
| Kelly, EA | 1 |
| Weise, CC | 1 |
| Loprete, FP | 1 |
| Palm, C | 1 |
| Andersen, T | 1 |
| Lingjaerde, O | 1 |
| Daneman, EA | 1 |
| Kellner, R | 1 |
| Descloux, A | 1 |
| Frommer, EA | 1 |
| Suwa, K | 1 |
| Toru, M | 1 |
| Kramer, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study[NCT03489044] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-10-28 | Active, not recruiting | ||
| Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability[NCT02002819] | Phase 2 | 34 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | -1.0 |
| Placebo (Epileptiform Activity) | 1.5 |
Blood samples intended for Quest Diagnostics LEV and prolactin serum levels (one 6 mL tube) will be processed in the following manner, as outlined in the Quest Diagnostics lab manual. The whole blood will be allowed to clot for 60 minutes and centrifuged at 2200 - 2500 revolutions per minute (RPM) for at least 15 minutes. The resulting serum will be split into 2 cryovials which will be stored at -20°C and immediately shipped for external assessment of LEV and prolactin levels. Prolactin will be assessed via immunoassay. The concentration of LEV in serum will be measured using validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) methods. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | ng/mL (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.2 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.2 |
| Placebo | 0.8 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) - The ADCS-ADL rating instrument (Galasko et al. 1997) will be used to evaluate functional capacity. The ADCS-ADL is a caregiver rated questionnaire. Scores on the 24-item ADCS-ADL range from 0 to 78. A higher score indicates less severity while a lower score indicates greater severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.4 |
| Placebo | 0.3 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) - The ADCS-CGIC is a seven-point scale that gives a global rating of change from baseline (Schneider et al. 1997). The baseline and follow up assessments are based on interviews with the subject and the informant. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 4.0 |
| Placebo | 4.0 |
Neuropsychiatric Inventory (NPI) - The NPI (Cummings et al. 1994) will be used to evaluate the severity of behavioral symptoms. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.8 |
| Placebo | 0.2 |
A 20-minute computer-based virtual navigation test will be used to assess how well a subject can navigate a virtual community to reach a goal destination. The subjects will then be measured on their ability to accurately navigate the virtual community after a period of a few hours. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | correct turns (Mean) |
|---|---|
| No Epileptiform Activity | -6.0 |
| Epileptic Activity | 17.4 |
"Epileptiform activity will be measured using a 1-hr resting magnetoencephalogram/electroencephalogram (M/EEG). M/EEG can detect abnormal epileptiform findings called spikes. The M/EEG will be read by an epileptologist with specialized training to assess whether there are any spikes. If spikes are observed during the M/EEG they will be counted to determine their frequency (e.g., 5 spikes per 1 hour recording). The frequency of spikes will then be compared to baseline values from before beginning the study treatment, using statistical tests to determine if the frequency changed with treatment." (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | Epileptiform events (Mean) |
|---|---|
| Levetiracetam | -0.1 |
| Placebo | -0.2 |
Changes in executive function were measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: antisaccade , set shifting , flanker task, dot counting, spatial 1-back, category fluency, and letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory. For this study, scores with SEs greater than 0.55 were classified as unreliable and excluded from analysis. Composite scores from 2 participants were excluded on this basis.The EXAMINER ranges for the participants in the study were -2.59 to 1.33. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.06 |
| Placebo | -0.14 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 1.5 |
| Placebo | -1.4 |
Clinical Dementia Rating Sum of Boxes (CDR-SOB) - The CDR will be used as a global measure of dementia severity (Morris 1993). The CDR consists of questions addressed to the caregiver/informant. The lowest score one can receive is a 0 and the highest is a 3. Score is measured by getting the mean of the individual scores in each category. Lower scores equate to less dementia severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.1 |
Changes in executive function will be measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: NIH EXAMINER - antisaccade , NIH EXAMINER - set shifting , NIH EXAMINER - flanker task, NIH EXAMINER - dot counting, NIH EXAMINER - spatial 1-back, NIH EXAMINER - category fluency, and NIH EXAMINER - letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory (Kramer et al. J Int Neuropsychol Soc. 2014;20(1):11-19. doi:10.1017/S1355617713001094). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| No Epileptiform Activity | -0.01 |
| Epileptiform Activity | 0.22 |
The One Day Fluctuation Assessment Scale will be used to quantitate fluctuations of dementia symptoms (Walker et al. 2000). The One Day Fluctuation Assessment Scale has a score range of 0-21 points,with higher scores indicatingmore fluctuations. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.3 |
| Placebo | -0.4 |
Two standardized methods will be used to quantitate fluctuations of dementia symptoms: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale (Walker et al. 2000). : The Clinician Assessment of Fluctuation (score range,0-12 points, with higher scores indicating more fluctuations),26 the One Day Fluctuation Assessment Scale (score range,0-21 points, with higher scores indicatingmore fluctuations). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.9 |
| Placebo | 0.1 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. The mean below represents the average change in score between the timepoints for all participants. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | 4.7 |
| Placebo (Epileptiform Activity) | -2.6 |
4 reviews available for phenobarbital and Depression
| Article | Year |
|---|---|
Topiramate and other kainate receptor antagonists for depression: A systematic review of randomized controlled trials.
Topics: Depression; Humans; Imipramine; Phenobarbital; Quality of Life; Randomized Controlled Trials as Topi | 2022 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2021 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2021 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2021 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2021 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2018 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2016 |
10 trials available for phenobarbital and Depression
| Article | Year |
|---|---|
[Experience with the use of new Bulgarian psychotropic drugs].
Topics: Adolescent; Adult; Aminopyrine; Aminoquinolines; Child; Clinical Trials as Topic; Depression; Dipyro | 1982 |
Influence of doctors' and patients' attitudes in the treatment of neurotic illness.
Topics: Amitriptyline; Amobarbital; Anxiety Disorders; Attitude; Chlordiazepoxide; Clinical Trials as Topic; | 1967 |
Diphenylhydantoin and phenobarbital in the relief of psychoneurotic symptoms. A controlled comparison.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Clinical Trials as Topic; Conversion Disorder; Depressio | 1972 |
[Prudent use of drugs against anxiety].
Topics: Anxiety; Chemical Phenomena; Chemistry; Depression; Diazepam; Evaluation Studies as Topic; Humans; H | 1973 |
Sleep in psychotic patients: a comparative clinical study.
Topics: Amitriptyline; Anxiety Disorders; Clinical Trials as Topic; Depression; Humans; Hypnotics and Sedati | 1967 |
A comparative trial of imipramine and phenobarbital in depressed patients seen in general practice.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Anxiety; Child; Clinical Trials as Topic; Depression; | 1969 |
Nitrazepam (Mogadon) as a sleep-inducing agent. An analysis based on a double-blind comparison with phenobarbitone.
Topics: Adult; Benzazepines; Clinical Trials as Topic; Depression; Female; Humans; Hypnotics and Sedatives; | 1969 |
A comparative trial of medazepam (nobrium) in anxiety-depressive states.
Topics: Anxiety; Benzazepines; Clinical Trials as Topic; Depression; Humans; Phenobarbital; Tranquilizing Ag | 1969 |
1. Improvement criteria in drug trials with neurotic patients.
Topics: Amobarbital; Chlordiazepoxide; Clinical Trials as Topic; Depression; Evaluation Studies as Topic; Hu | 1971 |
Treatment of childhood depression with antidepressant drugs.
Topics: Adolescent; Child; Child Behavior Disorders; Child Psychiatry; Child, Hospitalized; Chlordiazepoxide | 1967 |
22 other studies available for phenobarbital and Depression
| Article | Year |
|---|---|
A questionable diagnosis in a woman with drowsiness.
Topics: Benzodiazepines; Biomarkers; Depression; Diagnosis, Differential; Drug Overdose; Female; Humans; Mid | 2021 |
Depressive and anxiety reactions treated with nicotinic acid and phenobarbital.
Topics: Anxiety; Barbiturates; Depression; Humans; Niacin; Nicotinic Acids; North Carolina; Phenobarbital | 1953 |
A CONTROLLED CLINICAL TRIAL OF ALPHA METHYL DOPA IN PARKINSONIAN TREMOR.
Topics: Depression; Depressive Disorder; Hypnotics and Sedatives; Methyldopa; Parasympatholytics; Parkinsoni | 1963 |
PROCEDURE FOR WITHDRAWAL OF BARBITURATES.
Topics: Aged; Barbiturates; Depression; Electroconvulsive Therapy; Humans; Phenobarbital; Phenothiazines; Sc | 1964 |
[THERAPEUTIC EFFECTS OF A HYPNOTIC COMPOUND WITH TRANQUILIZING PROPERTIES].
Topics: Anxiety; Anxiety Disorders; Depression; Humans; Hypnotics and Sedatives; Meprobamate; Neurotic Disor | 1964 |
THE TIRED MOTHER.
Topics: Antidepressive Agents; Counseling; Depression; Depressive Disorder; Diagnosis; Fatigue; Humans; Marr | 1964 |
[DEPRESSION OF LACTATION WITH LUMINAL].
Topics: Breast Feeding; Depression; Depressive Disorder; Female; Humans; Lactation; Phenobarbital; Pregnancy | 1963 |
TEMPORAL LOBE EPILEPSY: A CLINICAL STUDY OF 47 CASES.
Topics: Adolescent; Biomedical Research; Birth Injuries; Depression; Depressive Disorder; Diagnosis, Differe | 1964 |
OBSERVATIONS OF PSYCHOMOTOR BEHAVIOR AS AN INDEX OF PSYCHOPHARMACOLOGIC ACTION.
Topics: Antidepressive Agents; Biomedical Research; Depression; Depressive Disorder; Dextroamphetamine; Drug | 1964 |
TRINURIDE IN THE TREATMENT OF MAJOR EPILEPSY.
Topics: Aggression; Anticonvulsants; Depression; Drug Therapy; Epilepsy; Epilepsy, Tonic-Clonic; Phenobarbit | 1965 |
Psychological factors and use of antiepileptic drugs: pilot work using an objective measure of adherence.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Anxiety; Culture; Depression; Drug Monitoring; Drug Therap | 2007 |
The effects of thyrotropin-releasing hormone (TRH) and other drugs on the actions of alcohol.
Topics: Animals; Brain; Cerebellum; Chlorpromazine; Cyclic GMP; Depression; Diazepam; Dose-Response Relation | 1980 |
[Experimental study of the "'rebound syndrome" following discontinuation of prolonged phenazepam administration and possibilities for preventing it].
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Chlorpromazine; Conditioning, Clas | 1981 |
Endogenous depression improvement and REM pressure.
Topics: Depression; Humans; Phenobarbital; Psychiatric Status Rating Scales; Sleep; Sleep Deprivation; Sleep | 1977 |
Plasma gamma-glutamyl transpeptidase elevation in patients receiving enzyme-inducing drugs.
Topics: Acyltransferases; Depression; Drug Synergism; Enzyme Induction; Epilepsy; Ethanol; Glutamates; Human | 1971 |
Myopathy associated with anticonvulsant osteomalacia.
Topics: Adult; Anticonvulsants; Back Pain; Depression; Electroencephalography; Electromyography; Ergocalcife | 1973 |
A comparison between the personality changes in certain forms of psychomotor and grand-mal epilepsy.
Topics: Adult; Depression; Electroencephalography; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic; Humans; | 1974 |
Antihypertensive drugs and depression.
Topics: Adult; Aged; Antihypertensive Agents; Bethanidine; Chlorthalidone; Depression; Diuretics; Drug Thera | 1974 |
Amitriptyline, diazepam, and phenobarbital sodium in depressed outpatients.
Topics: Absenteeism; Adult; Ambulatory Care; Amitriptyline; Antidepressive Agents; Depression; Diazepam; Eva | 1973 |
[Treatment of the psychosyndrome of alcoholic withdrawal using Atrium].
Topics: Aggression; Alcoholism; Anxiety; Barbiturates; Depression; Drug Combinations; Drug Evaluation; Human | 1971 |
A case of periodic somnolence whose sleep was induced by glucose.
Topics: Adolescent; Adult; Carbamazepine; Depression; Electroencephalography; Food Preferences; Glucose; Hum | 1969 |
Drugs, depression, and dream sequences.
Topics: Depression; Dreams; Female; Humans; Phenobarbital; Tranquilizing Agents | 1966 |